| Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy L Zammataro, S Lopez, S Bellone, F Pettinella, E Bonazzoli, E Perrone, ... Proceedings of the National Academy of Sciences 116 (45), 22730-22736, 2019 | 72 | 2019 |
| Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors C Li, E Bonazzoli, S Bellone, J Choi, W Dong, G Menderes, G Altwerger, ... Proceedings of the National Academy of Sciences 116 (2), 619-624, 2019 | 64 | 2019 |
| Preclinical activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) linked to the active metabolite of irinotecan … E Perrone, S Lopez, B Zeybek, S Bellone, E Bonazzoli, S Pelligra, ... Frontiers in Oncology 10, 118, 2020 | 46 | 2020 |
| PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib A Bianchi, S Lopez, G Altwerger, S Bellone, E Bonazzoli, L Zammataro, ... Gynecologic oncology 155 (1), 144-150, 2019 | 40 | 2019 |
| Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan B Zeybek, A Manzano, A Bianchi, E Bonazzoli, S Bellone, N Buza, P Hui, ... Scientific reports 10 (1), 973, 2020 | 39 | 2020 |
| Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas S Lopez, E Perrone, S Bellone, E Bonazzoli, B Zeybek, C Han, ... Oncotarget 11 (5), 560, 2020 | 36 | 2020 |
| Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial … E Perrone, P Manara, S Lopez, S Bellone, E Bonazzoli, A Manzano, ... Molecular oncology 14 (3), 645-656, 2020 | 27 | 2020 |
| In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma C Han, E Perrone, B Zeybek, S Bellone, J Tymon-Rosario, G Altwerger, ... Gynecologic oncology 156 (2), 430-438, 2020 | 26 | 2020 |
| Inhibition of BET bromodomain proteins with GS-5829 and GS-626510 in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer E Bonazzoli, F Predolini, E Cocco, S Bellone, G Altwerger, G Menderes, ... Clinical Cancer Research 24 (19), 4845-4853, 2018 | 24 | 2018 |
| PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers E Bonazzoli, E Cocco, S Lopez, S Bellone, L Zammataro, A Bianchi, ... Gynecologic oncology 153 (1), 158-164, 2019 | 20 | 2019 |
| Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate … JR Tymon-Rosario, P Manara, DD Manavella, S Bellone, TMP Hartwich, ... Gynecologic Oncology 166 (1), 117-125, 2022 | 19 | 2022 |
| Proteomics reveal cap-dependent translation inhibitors remodel the translation machinery and translatome JJD Ho, TA Cunningham, P Manara, CA Coughlin, A Arumov, ER Roberts, ... Cell reports 37 (2), 2021 | 19 | 2021 |
| DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo J Tymon-Rosario, E Bonazzoli, S Bellone, A Manzano, S Pelligra, ... Gynecologic oncology 163 (2), 334-341, 2021 | 16 | 2021 |
| Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma E Bonazzoli, S Bellone, L Zammataro, B Gnutti, A Guglielmi, S Pelligra, ... Gynecologic oncology 158 (3), 769-775, 2020 | 4 | 2020 |
| The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo C Han, B McNamara, S Bellone, J Harold, P Manara, TMP Hartwich, ... Gynecologic oncology 170, 172-178, 2023 | 3 | 2023 |
| The PARP inhibitor niraparib demonstrates preclinical activity against HRD-deficient carcinosarcomas JR Tymon-Rosario, P Manara, A Manzano, L Zammataro, E Bonazzoli, ... Gynecologic Oncology 159, 255, 2020 | 1 | 2020 |
| Abstract P23: RHOA inactivation subverts IFN-γ response and promotes antigen escape in CAR-T resistant diffuse large B-cell lymphoma AD Newsam, CA Coughlin, YE Goretsky, AY Alaoui, DE Tsai, DG Coffey, ... Blood Cancer Discovery 5 (2_Supplement), P23-P23, 2024 | | 2024 |
| Abstract C051: Alteration of protein translation by eIF4A1 inhibition exquisitely primes lymphoma cells to induction of ferroptosis P Manara, AM Barroso, AY Alaoui, OB Lightfuss, TA Cunningham, ... Molecular Cancer Therapeutics 22 (12_Supplement), C051-C051, 2023 | | 2023 |
| Enhanced Ferroptosis Induction Susceptibility in Diffuse Large B-Cell Lymphoma through Rocaglate-Mediated Translation Inhibition P Manara, A Barroso, AY Alaoui, TA Cunningham, DH Ho, K Hoffman, ... Blood 142, 2814, 2023 | | 2023 |
| Transcriptional response to rocaglate translation inhibitors in lymphoma shows cellular adaptation through induction of stress and survival pathways P Manara, TA Cunningham, JJD Ho, OB Lightfuss, AY Alaoui, JH Schatz Cancer Research 83 (7_Supplement), 4878-4878, 2023 | | 2023 |
